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CAM1 (IRF-1) is a tumor suppressor and transcriptional modulator that can regulate
gene expression involved in cell growth control, induction of apoptosis, and post-translation modiﬁcation. In
this study, we found that IRF-1 inhibits endothelial cell angiogenesis using human umbilical vein endothelial
cell (HUVECs) culture system. In addition, IRF-1 directly inhibited the tube formation of endothelial cells on
Matrigel and reduced the expression of p-Akt, and p-eNOS, which play a signiﬁcant role in angiogenesis
when stimulated by VEGF. We also demonstrate that C-terminal region including transactivation domain (TA)
of IRF-1 functions as a signal for its angiostatic activity, and is spliced in human tumor tissues. These ﬁndings
indicate that splicing variant involving exons 7 of IRF-1 could potentially modulate anti-angiogenic effect of
IRF-1. In overall, this study provides the ﬁrst evidence for anti-angiogenic role of IRF-1, which may have
therapeutic values for cancer and angiogenesis-associated diseases.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionInterferon regulatory factor-1 (IRF-1), the founding member of the
IRF family, is a transcription factor involved in cell growth regulation,
induction of apoptosis, immune responses, post-transcription mod-
iﬁcation, and cell transformation by oncogenes [1–5]. The best
characterized activity of IRF-1 is as a sequence speciﬁc DNA-binding
domain and transcriptional activator of certain IFN-stimulated genes
[6]. Accumulating evidence supports the theory that IRF-1 functions as
a tumor suppressor [7–10] and revert the transformed phenotype
[9,11–13]. In human tumors, IRF-1 is inactivated to prevent cell cycle
arrest and apoptosis by genetic alteration, such as gene and exon
deletion [10,14–16]. IRF-1 also has been shown to play roles in
regulating both ubiquitination and SUMOylation in cancer [5,17,18].
Angiogenesis, the formation of new blood vessels from pre-
existing vasculature, is a crucial step in tumor growth [19,20] and
progression because it enables the supply of oxygen and nutrients to
the growing tumor [21]. One of the key mediators of blood vessel
formation during development is vascular endothelial growth factor
(VEGF), which can stimulate the proliferation and migration in
endothelial cells [22]. In tumors, the activity of endothelial cells
plays an essential role for the regulation of various vascular biological
function and diseases.82 31 920 2337.
l rights reserved.IRF familymembers share signiﬁcant homologywith the N-terminal
120 amino acids, which comprise a DNA-binding domain (DBD)
characterized by ﬁve tryptophan repeats [2,23]. The DBD also revealed
as a region required for homodimerization and nuclear localization [24].
The C-terminus of IRF-1 contains a transactivation domain (TA) between
amino acids 185 and 256, but this amino acid region is not present in the
transcriptional repressor IRF-2. A functional antagonist of IRF-1 is IRF-2
[2], which functions as a tumor suppressor and as an oncoprotein
[11,25].
In the present work, we evaluated the role of IRF-1 during angio-
genesis using a human umbilical vein endothelial cell (HUVECs)
culture system with puriﬁed protein of IRF-1 in vitro. We found that
IRF-1 inhibited HUVECs migration and tube formation on Matrigel.
Further, we deﬁned the functional domains of IRF-1 causing
angiogenesis. This study may provide evidence for the potential
application of the IRF-1 as an anti-angiogenic therapy for the
angiogenesis-associated disease such as cancer.
2. Materials and methods
2.1. Cell culture and antibiotics
Human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics
(Walkersville, MD), and maintained on 0.3% gelatin (Sigma, St. Louis, MO) coated dishes
using the EGM-2 BulletKit medium (Clonetics) in an atmosphere of 5% CO2 in air at
37 °C. The EGM-2 BulletKit medium consists of a base medium containing 20μMHEPES
(Sigma), 5% heat inactivated fetal calf serum, and 1% Penicillin–Streptomycin (Gibco,
New York, NY). HUVECs were used for experiments at passages 3–5. The following
antibodies were used in this study: anti-IRF-1 (Santa Cruz Biotechnology, Santa Cruz,
Fig. 1. The effect of human IRF-1 on endothelial cell migration. (A) Various
concentrations of IRF-1 were used for the assays. Serum-starved HUVECs were plated
onto the Transwell plate with different doses of IRF-1 (25–200 ng/ml). After 24 h
incubation, HUVECs migrated to the 96-well chamber were calculated by a ﬂuorescence
staining and quantitation. The data are expressed as the means ± SD of three
independent experiments which were performed in duplicate. (B) In the time course,
serum-starved HUVECs were plated onto the Transwell platewith or without 100 ng/ml
IRF-1. HUVECs migration was investigated at 4, 6, 12, and 24 h. Each bar represents the
means ± SD. ⁎, P b 0.05 and ⁎⁎, P b 0.01 as compared to untreated cells.
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Cruz), anti-phospho-speciﬁc eNOS (Santa Cruz), anti-PI3K (Santa Cruz), anti-VEGF165
(Ab-1, Oncogene), anti-VEGF121 (Santa Cruz), anti-β-actin (Sigma), and anti-GFP (Santa
Cruz).
2.2. Small interfering RNA (siRNA) construction
The siRNA oligonucleotide sequence targeting IRF-1 (CTACTCCTTCCCTTTAATG)
corresponded to nucleotides 879 to 897 in the human sequence. siRNAwas synthesized
by using a siRNA Construction kit (Ambion, Austin, TX) and transfected by using the
RNAi shuttle (Orbigen, San Diego, CA) according to the manufacturer's protocols.
HUVECs were then transfected with GFP-IRF-1 or GFP-IRF-1 with siRNA transfection.
GFP imageswere captured using a ﬂuorescencemicroscope (Zeiss, Oberoken, Germany).
Total RNA was isolated using a TRIZOL Reagent (Life Technologies, Gaithersburg, MD)
and reverse transcription (RT) PCR was then performed. The transfection efﬁciency was
examined with respect to the expression level of co-transfected green ﬂuorescent
protein (GFP), which was conﬁrmed by immunoblotting with an anti-IRF-1 antibody.
2.3. Protein expression, puriﬁcation and biochemical analysis
DNA encoding the three splicing variants of IRF-1 and full-length IRF-1 were
isolated by polymerase chain reaction and subcloned into pET28a (Novagen) using
EcoRI and XhoI. Then each construct was expressed in Escherichia coli strain BL21 (DE3)
grown in Luria Bertani medium supplemented with kanamycin (75mg/ml). Culture was
grown at 37 °C to an A600 = 0.4 ~ 0.5, transferred at 30 °C, and were induced by the
addition of 0.4 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) for 4h. The induced
cells were then harvested and resuspended in 20 mM Tris–HCl (pH 8.0) containing 10%
glycerol, 50 mM NaCl, 0.1 mM EDTA, and 1 mM dithiothreitol. Cells were lysed by
ultrasonication, and were centrifuged for 15 min to remove cell debris. The supernatant
was ﬁltered and loaded onto a nickel afﬁnity column matrix (Invitrogen) and incubated
at 4 °C for 2h. The slurry was pelleted by centrifugation and washed with washing
buffer (20 mMNa2HPO4, pH 6.0, 500 mMNaCl) three times. The pellet of the gel matrix
was resuspended in elution buffer (20 mM Na2HPO4, pH 6.0, 500 mM NaCl containing
400mMimidazole) and incubated at 4 °C for 20min to elute the boundHis fusionproteins.
The His-tag was cleaved off with thrombin, and the each protein was further puriﬁed
using high performance liquid chromatography (Waters 600). Protein concentration
was determined by the Bradford assay with bovine serum albumin (Sigma) as a standard
(Bio-Rad).
2.4. Transient transfection and in vitro speciﬁc activity assay
Transient transfections of 70–80% conﬂuent HUVECs were performed using the
Fugene 6 Reagent (Roche, Mannheim, Germany) according to the manufacturer's
instructions. Luciferase reporter assay was performed as previously described [16]. The
HUVECs plated on 60-mm dishes and triply transfected using Fugene 6 Reagent with
full-length IRF-1 or its splicing variants (200 ng each), pGL-3 containing the interferon-
stimulated response element (150 ng), and pRL containing the Renilla luciferase cDNA
(50 ng). Twenty-four hours after transfection, the cells were harvested and dissolved in
40ml of 1× passive lysis buffer (Promega, Madison,WI). After lysis, the cell extracts were
incubatedwith luciferase substrate for 30min at room temperature. Lysateswere cleared
by centrifugation for 15 min at 14,000 rpm, and then a 10 μl aliquot of each sample was
transferred to a 96-well assay luminometer plate containing 50 μl/well of the provided
Luciferase Assay Reagent II. The provided Stop and Glo Reagent (50 μl/well) was then
added to initiate Renilla luciferase activity, and the ratio of ﬁreﬂy luciferase activity to
Renilla luciferase activity was calculated.
2.5. [3H]thymidine uptake assay
To measure cell proliferation [26], HUVECs were seeded at a density of 9 × 103 cells
per well in DMEM containing 5% heat inactivated fetal calf serum, and 1% Penicillin–
Streptomycin in the gelatinized plates on day 0. After 18h, cells were incubated for 6 h in
M199 containing 1% FBS and then stimulated with VEGF (10 ng/ml, R&D Systems,
Minneapolis, MN) for 24 h in M199 containing 1% FBS. [3H]thymidine (0.5 μCi/ml,
Amersharm, Arlington, IL) was then added 4h prior to the assay. High molecular mass
[3H]-radioactivity was precipitated using 5% trichloroacetic acid at 4 °C for 1 h. Cells
were solubilized in 0.2N NaOH and 0.1% SDS and [3H]thymidine uptake was evaluated
with a liquid scintillation counter (Beckman Instrument). Three independent experi-
ments were conducted in triplicate; values shown represent means ± SD of total cpm.
2.6. Migration and invasion assay
Migration and invasion were assayed using Transwells (Costar, 8 μm pore size) as
previously described [26]. For migration assays, the lower surface of a ﬁlter was coated
with 10 μg of gelatin. M199 containing 1% FBS with VEGF (25 ng/ml) was placed in the
lower wells. Cells were ﬁxed and stained with H&E. Non-migrating cells on the upper
ﬁlter surface were removed by wiping with a cotton swab. The numbers of cells that
migrated to the lower side of the ﬁlter were counted under a light microscope and the
mean values of eight ﬁelds were determined. For the invasion assay, the lower and
upper surfaces of a ﬁlter were coated with 10 μg of gelatin and 10 μg of Matrigel (BD
biosciences), respectively. The ﬁxation and quantiﬁcation methods used were the sameas described for the migration assay. Three independent experiments were conducted
in triplicate; and the values shown represent means ± SD.
2.7. Tube formation assay
Growth factor-reduced Matrigel (200 μl of 10 mg/ml) was added to a 24-well plate
and polymerized for 30min at 37 °C. Untransfected, pEGFP, pEGFP-IRF-1, or siIRF-1-
transfected HUVECs (1×105 cells) were seeded on the surface of theMatrigel. Cells were
then incubated for 48 h with or without 10 ng/ml of VEGF in M199 containing 1% FBS.
Morphological changes were photographed at ×40 magniﬁcation. HUVEC tube lengths
were determined using an inverted microscope equipped with a digital CCD camera
(Zeiss) and quantiﬁed using ImageLab imaging software (MCM Design).
2.8. Ex vivo angiogenesis assay
A novel ex vivo angiogenesis assay using an explant culture of skeletal muscle on
Matrigel was done with some modiﬁcations, according to Jang et al. [27]. Six-week-old
BALB/c mice were anesthetized and the legs were shaved. The tibialis anterior muscle
was extracted and the cross-sections taken from the muscle were washed thrice with
PBS. The washed muscle was placed in a 24-well plate containing 200 μl of growth
factor-reduced Matrigel and polymerized for 30min at 37 °C. M199 containing 1% FBS
with or without 10 ng/ml of VEGF was added. After 6 days, outgrowths of capillary-like
structures were observed. The observed structures were then treated with Mock, IRF-1,
or IRF-1 siRNA for 5 days. The mean area of the microvessels was measured by
employing an optical imaging technique and the measurements were then quantiﬁed
using ImageLab imaging software. Independent experiments were repeated thrice and
each value represents the mean ± SD of triplicate samples.
2.9. Chick chorioallantoic membrane (CAM) assay
The CAM assay was performed with minor modiﬁcations [28]. Fertilized chick
embryos were pre-incubated at 37 °C with 70% humidity in order to conduct the
chorioallantoic membrane assay. After 3 days, a square window was opened after the
removal of 2–3 ml of albumin to detach the developing CAM from the shell. A
1.5×1.5 cm window in the shell was made to expose the CAM. Clear tape was used to
seal the windows that were formed and the eggs were incubated for 60 h. On day 8,
CAMs were implanted, under sterile conditions within a laminar ﬂow hood, with
sterilized Thermanox discs. Thermanox discs were loaded with 100 ng Mock, IRF-1, or
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CAM was examined daily until day 12 and photographed in ovo with an Axioskope2
plus microscope (Zeiss) equipped with color CCD camera (ProgResC14, Jenoptik,
Germany). Recombinant human VEGF (100 ng), incorporated into Thermanox discs,
induced branching of blood vessels. At a dose of 100 ng/disk, IRF-1 inhibited these
responses in 90% (n = 9/10) of CAMs. At similar dose, both Mock or siRNA-treated group
did not show angiogenesis inhibition (0%, n = 0/10). Two independent, blinded
investigators performed the count of blood vessels for each group.
2.10. Western blot analysis of PI3K, Akt, and eNOS phosphorylation
A Western blot analysis of PI3K, Akt, and eNOS was conducted. VEGF was used to
stimulate the HUVECs for 20 min. The cells were then lysed, and equal amounts of
protein were separated using SDS-PAGE. The separated protein was then transferred to
a nitrocellulose membrane. After incubation in blocking solution, membranes were
incubated with anti-PI3K, anti-p-Akt, and anti-p-eNOS antibody for 1.5 h at room
temperature. An ECL system (Amersham) was used for detection.Fig. 2. Activity of human IRF-1 domain on HUVECs. (A) Ablation of GFP-IRF-1 protein and
visualized under ﬂuorescence microscope, and analyzed the mRNA or protein expression lev
human IRF-1. Human IRF-1 (100 ng) was assayed on HUVECs in the presence of VEGF165 in a
scintillation counter. (C) and (D) To investigate whether overexpressed IRF-1 modulates the e
the migration assays (C) or on Matrigel-coated Transwell for the invasion assays (D) follow
invaded cells were counted under a light microscope and mean values were determined. ⁎,2.11. Total RNA extraction and RT-PCR
Total cellular RNAwas isolated using TRIZOL Reagent according to themanufacturer's
instructions, and 2 μg of total RNA was reverse transcribed in a reaction volume of 20 μl
using the Superscript II enzyme (Invitrogen). The resulting cDNAwas used as the template
for PCRampliﬁcationof the full-length IRF-1gene (forward5′-GCGCTCCGCGCGCCCTCACT-
3′ and reverse 5′-GCCAGGTCCTGCTTGCCTAG-3′), or two fragments of the IRF-1 encoding
gene (N-terminal half forward 5′-GCGCTCCGCGCGCCCTCACT-3′ and reverse 5′-
TAGCTGCTGTGGTCATCA-3′, comprising exons 2, 3, 4, and 5; C-terminal half forward 5′-
AAGTCATGTGGGGATTCCAG-3′ and reverse 5′-GCCAGGTCCTGCTTGCCTAG-3′ comprising
exons6, 7, 8, 9, and10). The three splicingvariantswere ampliﬁedusing theC-terminalhalf
forward primer and speciﬁc reverse primers (Δ7, 5′-TGTAGCTTCAGAGGTGGA-3′; Δ8, 5′-
CTCCAAGAGCTGGAGTCA-3′; Δ9, 5′-CCCAATATCCCCCCCTGG-3′). The PCR conditions
consisted of the indicated number of cycles at 95 °C for 30s, 61 °C for 30s (but 58 °C for
Δ9), and 72 °C for 30s. The resulting fragments were resolved by 1% agarose gel electro-
phoresis and conﬁrmed by automatic sequencing (ABI 373, PerkinElmer Life Sciences).mRNA expression by siRNA in HUVECs. Bar, 50 μm. After transfection, the cells were
els by RT-PCRs and immunoblots. (B) Inhibition of DNA synthesis in endothelial cells by
72h proliferation experiment. cpm value of [3H]thymidine was determined with a liquid
ffects of VEGF on endothelial cell migration and invasion, we tested using Transwells for
ed by stimulation with or without VEGF (25 ng/ml) for 48 h. Numbers of migrated or
Pb0.05; ⁎⁎, Pb0.01 compared with VEGF alone.
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The cDNAs encoding human VEGFR1 or VEGFR2 were constructed into pGilda
expression vector, respectively. The resulting plasmid pGilda-VEGFR1 or VEGFR2 were
introduced into yeast strain EGY48 [MATa, his3, trp1, ura3-52, leu2: :pLeu2-LexAop6/
pSH18-34 (LexAop-lacZ reporter)] by a modiﬁed lithium acetate method. The cDNAs
encoding B42-IRF-1 fusion protein were introduced into the competent yeast cells that
already contained pGilda-VEGFR1 or VEGFR2 and the tryptophan prototrophy (plasmid
marker) transformants were selected on a synthetic medium (Ura−, His−, Trp−) containing
2% glucose. The interaction between the VEGFR1 or VEGFR2 and IRF-1 was compared by
measuring the expression level of the two reporter genes. Theβ-galactosidase activitywas
determined according to the method as described [29]. Yeast cells containing each of the
constructions were cultured in SD media until they reached a mid-log phase. The culture
broth (0.4 ml) was taken and mixed with Z buffer (1.4 ml) containing 2-mercaptoethanol.
Chloroform (100 μl) and 0.1% SDS (100 μl) were added to the mixture, and the cells
were vortex mixed for 45s. The reaction substrate O-nitrophenyl β-D-galactopyranoside
(ONPG) (0.32 ml) was added and the reactionwas carried out at 30 °C until a yellow color
appeared, and was then quenched by adding 1M Na2CO3. Samples were then centrifuged
brieﬂy to remove cell debris, and the absorbance of the supernatant was measured at
420nm.
For co-immunoprecipitation, HUVECs were co-transfected with cDNA constructs of
pEGFPC1-IRF-1 and pcDNA4/HisMax-VEGGR1 or VEGFR2 using Fugene 6 Reagent. As a
negative control, pEGFPC1-IRF-1 and empty vector pcDNA4/HisMax were also co-
transfected. Two days after transfection, cells were harvested by trypsinization and
centrifugation. Cell pellets were washed in PBS, resuspended in cell lysis solution
(50mM Tris, pH 7.2,150mMNaCl,1% Triton X-100,1 μg/ml leupeptin, 1 μg/ml pepstatin,
2 μg/ml aprotinin, 200 μg/ml PMSF). Lysates were incubated with anti-His antibody
(Santa Cruz) and precipitated with protein A-agarose beads. Immunoprecipitates were
resolved by SDS-PAGE, and immunoblottedwith anti-GFP antibody or anti-His antibody
(Santa Cruz). An ECL system (Amersham) was used for detection.
2.13. s.c. tumor models and immunohistochemistry
Speciﬁc pathogen-free BALB/c and nu/nu mice were purchased from Biogenomics
(Seoul, Korea) and Charles River Labs (Wilmington, MA), respectively. To establish
tumors in mice, 1×106 of 2774 tumor cells were injected s.c. in the mid-dorsal region.
Tumors were allowed to grow for 11 days. Then, an intratumoral injection of IRF-1 was
done thrice, once every 3 days. Tumor growthwas determined by calipermeasurements
every 3 days. Tumor volume was calculated by the following formula: tumor volume
(mm3) = (a×b2) / 2, where a = length in mm and b = width in mm. Tumor volume andFig. 3. IRF-1 inhibits tube formation in vitro and vessel sprouting ex vivo. (A) HUVECs were eith
reducedMatrigel and then treatedwith orwithout VEGF (10 ng/ml) for 48 h. The formation of
and are expressed as themeans±SD. ⁎, Pb0.05 comparedwith VEGFalone. (B) Cross-sections o
or without VEGF for 6 days and treated with Mock, IRF-1, or IRF-1 siRNA for 5 days. Outgrowt
×12.5 and ×40, top and bottom, respectively). Bar, 500 µm. Mean area of vascular sprouting wbody weight was measured every other day. Mice were sacriﬁced on day 24 after ﬁnal
injection. Tumors were then excised and prepared for immunohistochemistry.
2.14. Data and statistical analysis
All datavalues are presented as themean± SDormeans ± SEM. Statistical comparisons
were carried out using the Student's t-test. P b 0.05 were considered relevant.
3. Results
3.1. IRF-1 decreases the VEGF-induced migration of HUVECs in a
dose-dependent manner
In order to conﬁrm the effect of IRF-1 on HUVECs migration, cells
were treated with several concentrations of IRF-1 (25–200 ng/ml). We
observed that IRF-1 decreased the VEGF-induced migration of
HUVECs in a concentration-time-dependent manner and maximum
effect was at 100 ng/ml (Fig. 1A). To conﬁrm the above ﬁnding, we
investigated a time course at 4, 6, 12, and 24 h and observed an
inhibitory effect of IRF-1 (100 ng/ml) on cell migration (Fig. 1B). After
24 h of treatment with increasing concentrations (25–200 ng/ml) of
IRF-1, no cell migration change was observed in the treated sample
(data not shown). The results indicate that VEGF-induced endothelial
cell migration is speciﬁcally inhibited by IRF-1, whereas was not
caused by its cytotoxic effect.
3.2. IRF-1 inhibits VEGF-induced proliferation, migration, and invasion of
HUVECs
To further conﬁrm the effect of IRF-1 on endothelial proliferation,we
used RNA interference. As shown in Fig. 2A, siRNA markedly inhibited
the expression of GFP-IRF-1 protein and mRNA in HUVECs (lane 2).
However, siRNA did not affect the expression of an irrelevant gene
(GAPDH). HUVECs were either untreated or treated with Mock, IRF-1 orer untreated or treated withMock, IRF-1, or IRF-1 siRNA, were seeded on growth factor-
tubular structureswas detected by an invertedmicroscope. Tube lengthswere quantiﬁed
fmouse tibialis anteriormusclewere embedded in growth factor-reducedMatrigelwith
h of capillary-like structures was observed with an invertedmicroscope (magniﬁcations,
as quantiﬁed and expressed as the means±SD. ⁎, Pb0.05 compared with VEGF alone.
Fig. 5. IRF-1 interacts with VEGFR2 in vivo and in vitro. (A) Testing the interaction
between IRF-1 and VEGFR2 in the yeast two-hybrid system. Positive interactions were
revealed by observing cell growth over 3 days at 30 °C on medium lacking leucine, and
with the formation of blue colonies on medium containing X-gal (left). β-galactosidase
activity was then measured adding O-nitrophenyl β-D-galactopyranoside (ONPG)
(right). (B) Co-immunoprecipitation of IRF-1 with VEGFR2 and VEGFR1. Lane 1; lysate
from pEGFPC1-IRF-1 and pcDNA4/HisMax (vector only) co-transfectant, 2; lysate from
pEGFPC1-IRF-1 and pcDNA4/HisMax-VEGFR2 co-transfectant (left), Lane 1; lysate from
pEGFPC1-IRF-1 and pcDNA4/HisMax (vector only) co-transfectant, 2; lysate from
pEGFPC1-IRF-1 and pcDNA4/HisMax-VEGFR1 co-transfectant (right). IP means ‘immu-
noprecipitation’ and WB means ‘immunoblotting’ with the indicated antibodies.
Fig. 4. Angiostatic activity of IRF-1 in the chicken chorioallantoic membrane (CAM)
assay. (A) Digital images of in vivo angiogenesis assay in CAM. The open box indicates
the point at which the Mock, IRF-1, or siIRF-1-treated coverslips were loaded onto the
CAM of the developing eggs. (B) A quantitative evaluation of the angiostatic activity. The
data are presented as the mean number of blood vessel branches±standard deviations
from 6 to 9 embryos in each sample. The VEGF-treated vector (Mock) was only used as a
positive control. ⁎, Pb0.05 compared with VEGF alone.
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synthesis was assayed using [3H]thymidine incorporation (Fig. 2B). The
VEGF-induced DNA synthesis was observed in both untreated HUVECs
and empty Mock-treated HUVECs when compared with those of
unstimulated cells [30]. Overexpression of IRF-1 markedly inhibited
VEGF-induced DNA synthesis. This inhibitory effect was not due to the
cytotoxicity of IRF-1 in endothelial cells, since IRF-1 had no effect on the
viability of HUVECs in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay (data not shown). In addition, IRF-1 did not
exhibit cytotoxic effects on other normal cell types tested, such as
normal ﬁbroblasts, MRC-5 and IMR-90 (data not shown). The inhibitory
effect of IRF-1 on VEGF-induced endothelial cell proliferation was
completely recovered by siRNA infection. The results indicate that IRF-1
speciﬁcally inhibits VEGF-induced endothelial cell proliferation.
To investigate whether overexpressed IRF-1 modulates the effects
of VEGF on endothelial cell migration and invasion, we conducted
Transwell migration and invasion assays. VEGF enhanced the migra-
tion (Fig. 2C) and invasion (Fig. 2D) of untreated HUVECs and of empty
Mock-treatedHUVECswhen comparedwith that of unstimulated cells.
However, overexpression of IRF-1 signiﬁcantly reduced VEGF-induced
migration and invasion ofHUVECs. The ablation of overexpressed IRF-1
by siRNAmaintained the stimulatory effects of VEGF onmigration and
invasion of HUVECs. Therefore, the overexpression of IRF-1 potently
inhibited key events of the angiogenic process induced by VEGF, such
as proliferation, migration, and invasion of endothelial cells in vitro.
3.3. IRF-1 inhibits tube formation in vitro and vessel sprouting ex vivo
To conﬁrm IRF-1′s direct anti-angiogenic effects, we investigated
whether overexpression of IRF-1 could alter endothelial tube formation.
Untreated or empty Mock-treated cells incubated with VEGF formed an
organized network of endothelial cells on Matrigel (Fig. 3A). In contrast
however, overexpression of IRF-1 markedly inhibited VEGF-inducedtube formation. The inhibitory effect of IRF-1 on VEGF-induced tube
formation was completely recovered by siRNA transfection.
To evaluate whether IRF-1 inhibits vessel sprouting, an ex vivo
explant assay [27] was done (Fig. 3B). A vast amount of vessel sprouting
was detected in empty Mock-treated explants in the presence of VEGF.
Overexpression of IRF-1 showed signiﬁcantly reduced VEGF-induced
vessel sprouting, and was almost recovered by siRNA. These observa-
tions suggest that IRF-1 effectively suppressed capillary formation in
vitro and ex vivo.
3.4. Angiostatic activity of IRF-1 in the chicken chorioallantoic membrane
(CAM) assay
Chick CAM assays were performed to test for angiostatic activity of
IRF-1 on in vivo angiogenesis. As shown in Fig. 4, VEGF-induced
angiogenesis in CAMs were clearly inhibited by about 80%. Again,
activity was completely recovered by IRF-1-siRNA treatment. These
observations suggest that IRF-1 effectively suppressed the formation
of blood vessels in vitro and in vivo.
3.5. IRF-1 interacts with VEGFR2
We next tried to determine the mechanism involved in the
inhibition of angiogenesis by identifying proteins which bind to IRF-1.
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hybrid system. One prominent gene identiﬁed was VEGFR2. The
interactions between IRF-1 and VEGFR2 were examined bymeasuring
the relative expression levels of β-galactosidase and by co-immuno-
precipitation. As shown in Fig. 5A, β-galactosidase activity indicated
interactions between IRF-1 and VEGFR2, which were fully observed,
whereas little β-galactosidase activity was observed from the interac-
tions between IRF-1 and the empty vector (vector only). VEGFR1 was
used to conclude the binding speciﬁcity of IRF-1 to VEGFR2. IRF-1 was
shown to bind VEGFR2 but not VEGFR1 as illustrated in Fig. 5A.
For co-immunoprecipitation, cDNA constructs of IRF-1 (pEGFPC1-
IRF-1) and VEGFR1, 2 (pcDNA4/HisMax-VEGFR1, 2), along with
pEGFPC1-IRF-1 and vector only (pcDNA4/HisMax) were co-trans-
fected into HUVECs. Likewise, as above, IRF-1 was used to conﬁrm the
speciﬁcity of VEGFR2′s binding to IRF-1. Subsequently, immunopre-
cipitationwas also performed using an anti-GFP antibody with lysates
from both transfected cells. After immunoprecipitation, precipitated
proteins were immunoblotted using anti-VEGFR1, 2 and anti-IRF-1
antibodies. As shown in Fig. 5B, pcDNA4/HisMax-VEGFR2 was co-
immunoprecipitated with pEGFPC1-IRF-1 (lane 2, upper left panel),
whereas no interaction was observed between pcDNA4/HisMax
(vector only) and pEGFPC1-IRF-1 (lane 1, upper left panel). Immuno-
blotting using anti-IRF-1 antibody conﬁrmed that an equal amount of
IRF-1 was precipitated in both samples (middle left panel). Whole cell
lysates from both samples contained equivalent amounts of protein as
determined through immunoblotting using anti-β-actin antibody
(lower left panel). Also shown in Fig. 5B (upper right panel), is the
comparison made with VEGFR1. The panel clearly shows the absence
of binding between VEGFR1 and IRF-1. Taken together, our results
strongly suggest that the interaction between IRF-1 and VEGFR2 is
highly speciﬁc.Fig. 6. IRF-1 interfereswith VEGF-mediated PI3K-Akt signaling in HUVECs. (A) HUVECswere tra
for 20min. PI3K (p85) were detected byWestern blot analysis. Detection of the tubulin protein
Phosphorylated Akt and eNOSwere visualized by immunoblotting with antibodies that were sp
protein served as a loading control (Akt, eNOS). Each band indexwas calculated by computer-as
representative of three separate experiments. Data is shown as means±SEM. ⁎, Pb0.05; ⁎⁎, Pb3.6. IRF-1 inhibits PI3K/Akt signaling pathway
Based on the ﬁndings presented, we ﬁrst investigated whether the
human IRF-1 inhibits Akt upstream phosphatidylinotidol 3-kinase
(PI3K). PI3K pathway is implicated in upregulating VEGF [31]. As
shown in Fig. 6A, VEGF-stimulated PI3K activation was markedly
reduced by overexpressed IRF-1. Akt is one of the important down-
stream targets of PI3K. We also determined whether IRF-1 inhibits the
phosphorylation of Akt (Ser-473) and eNOS (Ser-1172). For example,
eNOS, endothelial NO synthase, inhibitors block endothelial cell
migration, proliferation, and tube formation that are induced by VEGF
in vitro as well as in vivo. As a result, the conclusion that VEGF induced
phosphorylation of Akt and eNOS plays a key role in VEGF-stimulated
angiogenesis can bemade. As presented in Fig. 6B, VEGF-stimulated Akt
and eNOS phosphorylation were dramatically reduced by the IRF-1.
Therefore, it seems that IRF-1 inhibits the PI3K/Akt signaling pathway in
HUVECs.
3.7. The exon 7 is essential for angiogenesis in vitro and reduces VEGF
expression in endothelial cells
We next used RT-PCR to examine splicing variants in 17 human
uterine cervical tissue samples (5 normal and 12 cancerous samples).
Previously, our results revealed that all tested cervical cancer tissue
samples showed a trio of lower bands in addition to the major wild-
type band [16]. In contrast, the uterine myometrial tissue samples did
not yield any IRF-1 splicing variants. Thus, this alternative splicing
may be tissue speciﬁc. To facilitate characterization of the IRF-1
splicing variants in cervical cancer, we subcloned the Δ7, Δ8, and Δ9
variants and the wild-type into pEGFP expression vectors, which were
then transfected into HUVECs. To conﬁrm IRF-1′s direct anti-nsfectedwithMock, IRF-1, or siIRF-1 for 48 h followed by treatmentwith VEGF (50 ng/ml)
served as a loading control. (B) HUVECs were stimulated for 20minwith VEGF (50 ng/ml).
eciﬁc for the phosphorylated protein (p-Akt, p-eNOS). Detection of the unphosphorylated
sisted densitometric signal intensities of PI3K, p-Akt, and p-eNOS (lower panel). Results are
0.01 compared with VEGF alone.
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splicing variants could alter endothelial tube formation. Empty Mock-
treated cells incubated with VEGF formed an organized network of
endothelial cells on Matrigel (Fig. 7A). In contrast however, over-
expression of IRF-1 and IRF-1(Δ7) markedly inhibited VEGF-induced
tube formation. The inhibitory effects of IRF-1 and IRF-1(Δ7) on VEGF-
induced tube formation were completely recovered by IRF-1(Δ8) and
IRF-1(Δ9) transfection. In order to ﬁnd the key exons in the IRF-1, all of
the IRF-1 splicing variants revealed the protein expression in HUVECs.
The protein encoded by Δ7, Δ8, and Δ9 could be visualized using an
anti-IRF-1 antibody (Fig. 7B). Consistent with these ﬁndings, over-
expression of IRF-1(wt) and IRF-1(Δ7) is shown to completely inhibitFig. 7. Anti-angiogenic effects of alternative splicing variants on the VEGF-induced tube
formation in HUVECs. (A) The HUVECs were plated onto 48-well and pre-coated with
Matrigel. Next, HUVECs were incubated with Mock, IRF-1(wt), or each alternative
splicing variant (Δ7, Δ8, Δ9- 100 ng) in the presence or without VEGF (10 ng/ml) for
48 h. The formation of tubular structures was detected by an inverted phase contrast
microscope image (top panel). The bar graph indicates the total length of the tubes
formed by the HUVECs (bottom panel) and expressed as the means±SD. ⁎, Pb0.05
compared with VEGF alone. (B) The total cell lysate of HUVECs in A was used for VEGF
detection.
Fig. 8. IRF-1 suppresses tumor growth and angiogenesis in vivo. Intratumoral injection
of IRF-1 inhibits s.c. 2774 human ovarian carcinoma growth as xenografts in nude mice
(n=8). Mean tumor volume was determined by caliper measurements (upper panel).
Frozen sections of the tumors were stained for endothelial cells using an anti-CD31
antibody (lower panel). ⁎, Pb0.05 compared with Mock.VEGF expression in HUVECs, the IRF-1(Δ8) and IRF-1(Δ9) splicing
variants did not (Fig. 7B). These indicate that IRF-1(wt) and IRF-1(Δ7)
inhibits theautocrineeffectof VEGF in endothelial cells and thus, a direct
anti-angiogenic effect. These results strongly suggest that the exon 7
within the C-terminal region of IRF-1 is involved in the activation of
angiogenic signaling in vitro and in vivo.
3.8. IRF-1 suppresses tumor growth and associated angiogenesis
To explore whether IRF-1 has direct antitumor activity, we tested
the effects of overexpressed IRF-1 on tumor cell growth in vitro. We
found that IRF-1 markedly decreased 2774 ovarian cancer cell growth
when compared with controls (data not shown).
The anti-angiogenic activity of IRF-1 was then evaluated in vivo.
2774 cells were implanted s.c. in nudemice. We allowed the tumors to
grow until they reached a mean volume of 100 mm3. On day 11, an
intratumoral injection of IRF-1was done and repeated every 3 days for
9 days. Tumors from IRF-1-treated mice were excised on day 24 after
the ﬁnal injection. The volume of IRF-1-treated tumors was 80%
smaller than those from Mock mice (Fig. 8). Moreover, immunohis-
tologic staining of endothelial cells in the IRF-1-treated mice showed
an 85% decrease in the number of blood vessels stained with anti-
CD31. Taken together, these results show that overexpressed IRF-1
potently inhibits tumor growth and angiogenesis in vivo.
4. Discussion
IRF-1was theﬁrstmember of the IRF family, and originally identiﬁed
as a regulatorof IFNα/β and its homolog IRF-2 [3]. Functional antagonist
of IRF-1 as a tumor suppressor is IRF-2. IRF family diverse expressions
could be due to their multifunctional properties with respect to cell
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tion by oncogenes [32,33]. Recently, it was reported that SUMOylated
IRF-1 interferes with IRF-1-mediated apoptosis in tumor cells. The
SUMOylated protein represses IRF-1-mediated transcriptional activa-
tion and apoptosis [5]. Thus, IRF-1 of tumor suppressor can enhance the
tumor cell evasion of immune system. It is known that IRF-1 is
frequently inactivated to prevent apoptosis by genetic alteration such as
exon deletion in human cancer populations [10,14–16].
In this study, IRF-1 signiﬁcantly inhibited endothelial cell migra-
tion in dose–time-dependent manner. In addition, IRF-1 directly
inhibited the tube formation of endothelial cells on Matrigel and
reduced the expression of VEGF, p-Akt, and p-eNOS in HUVECs. Akt
and eNOS play a signiﬁcant role in angiogenesis when stimulated by
VEGF. VEGF is known to stimulate Akt dependent phosphorylation of
eNOS, therefore activating eNOS. The observations from our study
show that IRF-1 had little to no effect on unphosphorylated Akt and
eNOS. Once phosphorylated though, p-Akt produced a faint expres-
sion of protein, and it was observed that protein expression became
fainter when p-Akt was associated with IRF-1. Phosphorylation of
eNOS also showed protein expression like p-Akt, and the expression
decreased as it was associated with IRF-1. These data indicate that IRF-
1 have a directly inhibitive effect on angiogenesis in vitro. We also
observed that exogenous IRF-1 has a direct inhibitive effect on
endothelial cell migration and tube formation, and using a CAM
model. Endothelial cell proliferation and migration are initial steps
critical to the angiogenesis process.
To further examine the biological signiﬁcance of the splicing
variants of IRF-1 in cancer, we performed two types of methods
relevant to its physiological functions of tube formation and expres-
sion level of VEGF via Western blot. Our results revealed that the
variants differed in their abilities to angiogenic effect (Fig. 5A). In
addition, VEGF protein expression followed an induction pattern
similar to the angiostatic activity of IRF-1 and its splicing variants
(Fig. 5B). Here we also demonstrate that C-terminal region including
transactivation domain (TA) of IRF-1 functions as a signal for its
angiostatic activity is spliced in human tumor tissues. These ﬁndings
suggest that splicing variant involving exon 7 could potentially
modulate IRF-1 anti-angiogenic effect.
Recently, many molecules that inhibit tumor angiogenesis have
been identiﬁed and characterized. These include antagonists of
angiogenic growth factors, receptors, integrin-adhesion molecules,
and matrix proteinases, some of which are currently subjects of
clinical trials [34,35]. However, one of themajor challenges in terms of
designing such therapies is that there are numerous direct and
indirect mechanisms by which tumors can induce new blood vessel
growth. It is therefore reasonable to assume that successful anti-
angiogenic protocols must address each of the possible mechanisms
by which tumors can induce new blood vessel growth. These new
therapeutic agents could prospectively be added to chemotherapy or
radiotherapy regimens, or could also be used in combination with
immunotherapy or vaccine therapy.
In summary, the results of the present study show that exogenous
human IRF-1 exerts a direct anti-angiogenic effect on endothelial cells
by inhibiting cell proliferation, migration, tube formation in vitro, and
vessel sprouting ex vivo, and CAM in vivo. We also have shown that
alternative splicing of IRF-1 in the region of exon 7 could potentially
regulate anti-angiogenic effect. This study provides further evidence
for anti-angiogenic role of IRF-1, which may have therapeutic values
for cancer and angiogenesis-associated diseases.
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